Sanne De Jongh

Sanne joined Oxford Science Enterprises in February 2023, bringing over 9 years of biotech investment experience.

At OSE, Sanne is responsible for sourcing and structuring new spinout opportunities from the University of Oxford, as well as supporting the existing Life Sciences portfolio.

She joins OSE from specialist transatlantic investor Gilde Healthcare where she was an investment manager focused on biotech across a range of development stages, therapeutic areas, and modalities. At Gilde, she also set up the Fellowship program to offer scientists a route from academia into venture capital (VC), as well as to increase diversity in the profession. Prior to Gilde, Sanne spent three years at Anterra Capital, a transatlantic Food and Ag Tech VC firm, at which she focused on the creation and backing of biotech companies to improve the global food supply chain. Sanne began her career at M Ventures, the strategic corporate VC fund of Merck KGaA, focused on healthcare.

She holds a BSc in Biochemistry from Leiden University with a minor in Neurology, and MSc in Biochemical Engineering from Delft University of Technology, the Netherlands, graduating cum laude.